EG Stada Italia is involved in the pharmaceutical industry, offering products such as equivalent drugs, consumer healthcare items, and biosimilars, as self-described.

EG Stada Italia

Contraria Biotech develops vaccines and biopharmaceuticals targeting infectious diseases, with a focus on antimicrobial resistance. The company uses integrated technological platforms for product development.

Contraria Biotech

Genenta Science is a clinical stage immuno-oncology company developing a cell-based platform that harnesses the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. The platform is not restricted by tumor type or target antigen and enables sustained targeted expression of therapeutic payloads inside the tumor microenvironment.

Genenta Science

Haliatx is a biotechnology company that specializes in the discovery and development of novel therapeutics. The company leverages cutting-edge research in halogen chemistry to create innovative treatments for various diseases.

Metric
Company Name	EG Stada Italia	Contraria Biotech	Genenta Science	Haliatx
Symbol
MSH ID	IT:EGSTADA	COM:CONTRARIABIOTECH	COM:GENENTA	COM:HALIATX
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology	Biotechnology	Biotechnology
Country	IT	IT	IT	US
Stage
Employee Count				16
Website	egstada.it	contrariabiotech.com	genenta.com	haliatx.com
LinkedIn				halia-therapeutics-inc
Founders

Metric
Market Cap				163.63M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IT:EGSTADA

EG Stada Italia

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue